absenc
effect
vaccin
viral
infect
highlight
urgent
necess
design
develop
effect
antivir
drug
due
advanc
virolog
sinc
late
sever
key
event
viral
life
cycl
well
delin
number
molecular
target
valid
culmin
emerg
mani
new
antivir
drug
recent
year
inhibitor
enterovirus
rhinovirus
respons
half
human
common
cold
current
activ
investig
agent
target
either
viral
protein
rel
conserv
capsid
structur
mediat
viral
adsorptionunco
process
proteas
highli
conserv
among
differ
serotyp
essenti
viral
replic
great
potenti
becom
antipicornaviru
drug
syndrom
hand
foot
mouth
diseas
herpangina
howev
virus
also
caus
potenti
sever
lifethreaten
infect
mening
enceph
myocard
poliolik
syndrom
neonat
sepsi
human
rhinovirus
infect
caus
nasopharyng
syndrom
common
cold
gener
popul
age
although
rhinoviru
infect
selflimit
complic
could
still
occur
patient
asthma
congest
heart
failur
bronchiectasi
cystic
fibrosi
date
antivir
agent
approv
fda
treatment
either
enteroviru
rhinoviru
infect
clinic
treatment
direct
toward
symptomat
relief
promin
symptom
clinic
syndrom
step
viral
attach
uncoat
viral
rna
replic
protein
synthesi
replic
cycl
enterovirusesrhinovirus
serv
potenti
target
antivir
agent
follow
section
briefli
review
virolog
clinic
diseas
enterovirus
rhinovirus
capsidbindingproteaseinhibit
molecul
potenti
agent
drug
develop
enteroviru
rhinoviru
two
import
pathogen
within
famili
picornavirida
human
enterovirus
socal
inhabit
enter
tract
includ
poliovirus
type
coxsackievirus
serotyp
coxsackievirus
b
serotyp
echovirus
serotyp
number
enterovirus
tabl
enteroviru
reclassifi
hepat
viru
rhinovirus
socal
special
adapt
nasopharyng
region
import
etiolog
agent
common
cold
adult
children
serotyp
rhinovirus
exist
picornavir
genom
consist
singlestrand
posit
sens
messengeract
rna
viral
rna
small
protein
call
vpg
coval
attach
end
polyadenyl
terminu
genom
rna
vari
length
base
noncod
region
ncr
long
highli
structur
contain
cloverleaflik
structur
import
neg
strand
viral
rna
synthesi
intern
ribosom
entri
site
ire
essenti
direct
translat
mrna
ncr
short
rang
length
base
ncr
also
contain
secondari
structur
notabl
pseudoknot
play
role
control
viral
synthesi
replic
picornavirus
take
place
entir
cytoplasm
attach
host
cell
viral
genom
rna
uncoat
viral
capsid
posit
strand
viral
rna
translat
viral
protein
essenti
viral
gene
replic
product
new
viral
particl
genom
replic
mrna
synthesi
occur
small
membran
vesicl
induc
sever
viral
protein
singl
replic
cycl
rang
hr
speed
viral
replic
depend
mani
factor
viru
strain
environment
temperatur
ph
host
cell
type
multipl
infect
picornaviru
virion
spheric
shape
diamet
nm
viral
particl
lipid
envelop
enterovirus
acid
stabl
retain
infect
ph
lower
rhinovirus
contrast
labil
ph
less
capsid
picornavirus
compos
four
structur
viral
protein
name
capsid
contain
structur
protein
arrang
icosahedr
lattic
basic
build
block
picornavir
capsid
protom
contain
one
copi
shell
form
lie
inner
surfac
though
homolog
sequenc
form
common
structur
bbarrel
jelli
roll
main
structur
differ
loop
connect
bstrand
nand
ctermin
sequenc
extend
bbarrel
domain
amino
acid
sequenc
give
picornaviru
distinct
antigen
surfac
virion
promin
starshap
plateau
fivefold
axi
symmetri
surround
deep
depress
canyon
proven
polioviru
rhinoviru
canyon
serv
receptorbind
site
c
viral
rna
translat
long
polyprotein
singl
polyprotein
undergo
proteolysi
virusencod
proteas
fig
cleavag
tyrgli
pair
connect
coat
precursor
enteroviru
accomplish
viral
proteinas
cleavag
proteas
essenti
viabil
viru
remain
cleavag
glngli
pair
execut
viral
proteas
essenti
enteroviru
replic
sequenc
align
enteroviru
proteas
reveal
homolog
mammalian
proteas
therefor
proteas
potenti
target
drug
discoveri
addit
cleavag
viral
polyprotein
shown
pro
cleav
host
cell
protein
cleavag
prevent
recruit
ribosom
subunit
cap
mrna
cleavag
releas
ntermin
domain
bind
turn
bind
cap
cellular
mrna
event
shut
translat
host
cellular
mrna
viral
proteas
also
contribut
poliovirusinduc
apoptosi
polioviru
induc
apoptosi
cleavag
translat
initi
factor
wherea
polioviru
kill
cell
apoptosi
activ
caspas
similar
apoptot
pathway
also
demonstr
enteroviru
transient
express
proteas
result
trigger
apoptosi
proteas
induc
apoptosi
human
neural
cell
via
activ
caspas
rhinovirus
usual
caus
common
cold
enterovirus
may
caus
differ
clinic
manifest
list
tabl
ii
common
cold
summer
cold
pharyng
tonsil
croup
frequent
report
respiratori
ill
caus
human
rhinoviru
enteroviru
benign
symptom
may
persist
sever
day
result
interrupt
school
work
day
may
substanti
etiolog
studi
viral
respiratori
ill
rhinovirus
infect
found
top
caus
enterovirus
respons
approxim
upper
respiratori
infect
etiolog
identifi
group
coxsackievirus
common
caus
herpangina
howev
coxsacki
b
virus
echovirus
also
report
clinic
manifest
children
group
highest
incid
usual
abrupt
onset
fever
associ
sore
throat
dysphagia
malais
grayish
white
vesicl
seen
posterior
portion
palat
uvula
tonsillar
pillar
fever
last
day
symptom
begin
improv
day
recoveri
usual
within
day
onset
hfmd
one
common
diseas
children
especi
children
year
age
diseas
usual
mild
onset
associ
sore
throat
without
fever
scatter
vesicular
lesion
observ
mouth
hand
feet
hip
coxsackieviru
close
relat
genet
caus
agent
hfmd
howev
associ
tabl
ii
diseas
caus
enterovirus
sever
neurolog
diseas
enceph
mening
poliomyel
syndrom
even
fatal
pulmonari
edema
neurovirul
first
came
attent
bulgaria
peopl
die
poliolik
diseas
epidem
caus
cn
diseas
subsequ
occur
new
york
australia
europ
asia
unusu
epidem
hfmd
complic
fatal
myocard
pulmonari
edema
occur
malaysia
implic
etiolog
outbreak
larg
scale
hfmd
outbreak
taiwan
cox
presum
caus
hfmd
begin
enteroviru
epidem
howev
numer
sever
complic
later
found
follow
case
hfmd
patient
die
rapidli
outbreak
prove
major
caus
hfmd
outbreak
enterovir
mening
common
caus
asept
mening
occur
per
popul
annual
durat
ill
last
day
coxsackieviru
b
associ
asept
mening
infant
echoviru
import
pathogen
mening
onset
enterovir
meningitisi
usual
sudden
high
fever
c
fever
pattern
may
biphas
symptom
sign
may
includ
headach
nausea
vomit
stiff
neck
myalgia
rash
muscl
weak
asept
mening
caus
certain
enteroviru
serotyp
associ
particular
clinic
stigmata
enceph
due
enteroviru
infect
also
well
document
unlik
asept
mening
enterovir
enceph
may
profound
acut
diseas
longterm
sequela
ill
usual
begin
like
asept
mening
fever
symptom
central
nervou
system
cn
sign
includ
confus
weak
lethargi
drowsi
irrit
coma
seizur
may
also
occur
enterovir
meningitisenceph
usual
good
prognosi
howev
mention
previous
meningitisenceph
may
accompani
pulmonari
edema
lead
fatal
great
success
polioviru
vaccin
program
poliomyel
elimin
world
polio
widespread
wildtyp
polioviru
infect
asymptomat
polioviru
infect
result
paralysi
remain
infect
caus
mild
flulik
ill
paralyt
manifest
polioviru
infect
reflect
region
cn
sever
affect
overal
mortal
rate
spinal
poliomyel
bulbar
medullari
poliomyel
higher
mortal
rate
near
enterovirus
common
pathogen
caus
acut
myocard
neonat
young
infant
particularli
suscept
coxsackieviru
b
virusassoci
myocard
rtpcrbase
studi
endomyocardi
biopsi
autopsi
specimen
reveal
enterovirus
caus
acut
myocad
symptom
includ
palpit
chest
pain
fever
patient
recov
unev
small
percentag
patient
develop
congest
heart
failur
chronic
myocard
dilat
cardiomyopathi
f
hemorrhag
conjunct
among
enterovirus
enteroviru
coxsackieviru
common
pathogen
caus
hemorrhag
conjunct
clinic
manifest
caus
two
enterovirus
indistinguish
includ
eyelid
swell
lacrim
pain
eye
recoveri
usual
complet
within
week
onset
rare
case
develop
poliomyelitislik
ill
viral
infecti
diseas
infect
polioviru
hepat
b
viru
hbv
influenza
viru
type
b
vaccin
appear
effici
feasibl
way
diseas
prevent
human
rhinovirus
enterovirus
howev
protocol
may
difficult
follow
due
broad
spectrum
variant
date
least
distinct
serotyp
respect
human
rhinovirus
enterovirus
report
addit
numer
variant
highmut
rate
viral
replic
also
present
formid
challeng
develop
effect
vaccin
reason
effect
antivir
drug
treat
diseas
caus
infect
rhinovirus
enterovirus
possess
high
potenc
low
toxic
also
broad
spectrum
activ
common
mani
viral
pathogen
sever
step
life
cycl
picornavirus
includ
initi
attach
rna
polymer
polyprotein
process
could
target
potenti
antivir
therapi
past
two
decad
inhibit
viral
attachmentunco
blocker
interrupt
viral
replic
via
target
code
region
proteas
attempt
order
find
effect
antipicornavir
agent
howev
effort
met
littl
success
point
despit
disappoint
result
capsid
protein
consid
promis
therapeut
target
due
fact
pleconaril
drug
candid
win
seri
potenti
use
fight
cold
reach
advanc
stage
phase
iiiiv
clinic
trial
although
pleconaril
final
reject
safeti
concern
believ
underli
caus
advers
side
effect
structurebas
rather
targetbas
natur
remain
section
review
focu
current
effort
develop
smallmolecul
antivir
agent
particular
emphasi
chemic
structur
exert
biolog
activ
either
capsid
protein
proteas
capsidbind
molecul
block
viral
infect
inhibit
viral
uncoat
andor
viral
attach
cellular
receptor
host
cell
bind
site
capsidbind
compound
appear
hydrophob
pocket
insid
locat
canyon
floor
floor
pocket
section
contain
gh
loop
region
display
greatest
chang
viral
structur
induc
compound
bind
two
hypothes
propos
explain
capsid
binder
mediat
antivir
function
mention
term
uncoat
insert
compound
hydrophob
pocket
lead
increas
stabil
viral
particl
render
viru
resist
uncoat
process
necessari
releas
viral
rna
believ
uncoat
viral
particl
requir
certain
degre
capsid
flexibl
interact
capsid
binder
may
produc
compact
capsid
structur
limit
vacant
space
conform
chang
essenti
uncoat
take
place
attach
bind
inhibitor
pocket
may
induc
conform
chang
viral
canyon
floor
bind
site
cellular
receptor
molecul
identifi
major
rhinoviru
receptor
thu
prevent
adsorpt
virus
host
cell
among
capsidbind
compound
win
seri
compound
figur
play
remark
role
develop
antivir
agent
rhinoand
enterovir
infect
disoxaril
also
known
win
first
compound
famili
satisfactori
biolog
profil
enter
clinic
trial
compound
found
effect
vitro
rhinoand
enterovir
serotyp
test
also
show
oral
efficaci
prevent
induc
paralysi
mice
howev
clinic
studi
discontinu
due
appear
crystallurea
healthi
volunt
high
dosag
successor
win
subsequ
evalu
phase
ii
vivo
efficaci
two
rhinovirus
rv
one
enteroviru
coxsackieviru
compound
significantli
attenu
viral
titer
sever
cold
induc
coxsackieviru
fail
show
efficaci
either
rinhoviru
win
short
halflif
presum
due
acid
labil
oxazolin
ring
develop
clinic
use
owe
advers
effect
flush
rash
attempt
made
discov
hydrolyt
stabl
analogu
compar
antivir
potenc
studi
led
discoveri
seri
compound
resist
acid
condit
maintain
broad
spectrum
activ
win
regard
promis
candid
seri
select
treatment
rhinoand
enterovir
infect
unfortun
administ
oral
beagl
molecul
caus
hepatotox
side
effect
hepatotox
presumb
due
multipl
nitrogen
tetrazol
ring
metabol
product
result
win
drop
evalu
continu
search
structur
relat
bioisoster
molecul
reduc
hepatotox
win
also
refer
pleconaril
final
emerg
promis
new
drug
candid
treatment
human
enterovir
infect
addit
better
metabol
stabil
monkey
liver
microsom
assay
newli
develop
analogu
also
shown
potent
oxazolin
win
tetrazol
win
predecessor
varieti
rhinoand
enterovirus
pleconaril
given
oral
administr
current
develop
viropharma
treatment
diseas
associ
picornaviru
infect
drug
candid
latestag
clinic
trial
treat
viral
respiratori
infect
viral
mening
unfortun
even
though
pleconaril
demonstr
effect
shorten
number
day
patient
felt
sick
reduc
sever
symptom
approv
fda
market
due
safeti
concern
make
drug
fate
uncertain
consid
tremend
synthet
effort
made
well
two
decad
consum
develop
win
compound
unexpect
result
extrem
discourag
biota
scientif
manag
pti
ltd
lead
new
class
capsidbind
antivir
agent
shown
possess
broad
spectrum
activ
rhinovirus
fig
inhibit
hrv
serotyp
cytopath
effect
reduct
assay
ec
ngml
found
superior
pleconaril
ec
ngml
pirodavir
ec
ngml
potenc
viru
yield
reduct
assay
potent
inhibit
ec
valu
ngml
also
observ
cytotox
detect
much
higher
concentr
toxicopharmacokinect
studi
highor
bioavail
rat
dog
suggest
administ
oral
replac
oximesubstitut
phenyl
ring
variou
bicycl
heterocycl
ring
led
anoth
seri
compound
repres
biota
benzazol
fig
signific
activ
even
concentr
low
mgml
ic
evalu
two
class
ongo
result
disclos
recent
use
skeleton
win
compound
structur
templat
structurebas
drug
design
group
nation
health
research
institut
nhri
taiwan
gener
librari
virtual
compound
whose
minimumenergi
conform
bear
close
similar
shape
pocket
human
rhinovirus
may
fit
caviti
well
studi
result
develop
seri
imidazolidinon
deriv
shown
antivir
activ
ev
make
seri
extrem
signific
use
develop
potenti
antiev
agent
mani
children
taiwan
fell
victim
hfmd
asept
meningitisenceph
acut
flaccid
paralysi
result
fatal
identifi
major
pathogen
etiolog
case
young
children
appear
suscept
viru
infect
also
infect
sever
symptom
unfortun
epidem
outbreak
continu
isol
whole
island
year
round
mani
sever
case
caus
also
report
pleconaril
claim
possess
broadspectrum
activ
enterovirus
test
antivir
activ
howev
pleconaril
fail
neutral
cytopath
effect
cpe
cultur
cell
induc
isol
outbreak
taiwan
find
underscor
necess
develop
antivir
agent
use
materi
isol
local
strain
timecours
studi
show
imidazolidinon
effect
inhibit
earli
stage
viral
infect
suggest
surfac
protein
highli
like
molecular
target
type
compound
current
class
compound
activ
investig
evalu
potenti
therapeut
util
anoth
seri
capsidbind
compound
exemplifi
sch
fig
synthes
scheringplough
sch
phenoxyl
imidazol
compound
hydrochlorid
salt
form
watersolubl
molecul
inhibit
plaqu
format
select
enterovirus
cox
polio
echo
rhinovirus
hrv
rang
ic
mm
ic
mm
respect
administ
oral
mgkg
three
time
per
day
sch
protect
mice
infect
either
cox
echo
mortal
day
subsequ
sch
deriv
sch
fig
exhibit
potent
activ
panel
enterovirus
includ
polio
echo
cox
concentr
ic
rang
mgml
plaqu
reduct
assay
cytotox
assay
conduct
hela
rd
cell
show
ic
valu
mgml
sch
administ
oral
protect
mice
polio
enceph
mortal
day
surviv
rate
dose
mgkgday
respect
close
relat
analogu
sch
also
show
increas
pirodavir
r
predecessor
r
shown
figur
discov
janssen
research
foundat
compound
possess
signific
activ
inhibit
replic
mani
rhinoviru
serotyp
compar
r
pirodavir
show
improv
potenc
vitro
inhibit
rhinovir
serotyp
concentr
mgml
less
nasal
spray
given
six
time
day
day
patient
signific
reduct
viru
shed
occur
clinic
benefit
observ
lack
clinic
efficaci
pirodavir
could
due
lowwat
solubl
seri
make
difficult
administ
aqueou
formul
compat
respiratori
secret
andor
labil
ester
function
group
prone
rapid
hydrolysi
form
correspond
inact
acid
although
r
much
less
activ
rhinoviru
serotyp
rel
r
given
prophylact
found
effect
prevent
cold
human
volunt
challeng
rhinoviru
given
intranas
spray
sixtim
day
consecut
day
total
dose
mg
commenc
hr
viru
challeng
r
abl
suppress
symptom
hr
medic
ceas
studi
compound
formul
enhanc
water
solubl
independ
class
compound
share
common
piperazin
motif
r
discov
sandoz
forschungsinstitut
typifi
sdz
figur
novel
piperazinecontain
deriv
potent
select
inhibitor
seri
human
rhinoviru
serotyp
enterovirus
vitro
former
sdz
activ
rhinoviru
serotyp
hrv
ic
less
mg
ml
echoviru
ic
valu
mgml
latter
sdz
select
toward
human
rhinovirus
rel
broader
antivir
spectrum
hrv
serotyp
test
sdz
inhibit
ic
valu
equal
lower
mgml
ic
lower
mgml
similar
r
seri
sdz
also
typic
capsidbind
molecul
evid
individu
substanti
cocrystal
hrv
consider
conform
chang
bind
site
observ
hrv
sdz
complex
sdz
compound
length
fill
entir
hydrophob
pocket
includ
innermost
end
occupi
space
effici
long
antivir
agent
win
suggest
compound
fit
entir
pocket
might
affect
uncoat
process
viral
particl
sdz
also
found
bind
pocket
hrv
complex
structur
howev
innermost
portion
pocket
vacant
caus
less
alter
backbon
conform
compar
antivir
agent
analyz
structur
result
margin
effect
viral
uncoat
may
provid
explan
observ
timecours
studi
sdz
found
primarili
interfer
hrv
adsorpt
cell
instead
inhibit
viral
uncoat
compound
show
detect
cytotox
effect
mgml
dose
mgkg
reduc
echoviru
paralysi
shorten
mean
time
paralysi
mice
greater
protect
echoviru
death
achiev
either
low
dose
mgkg
given
day
high
dose
mgkg
administ
day
although
sdz
show
antivir
efficaci
mice
clinic
use
may
limit
due
narrow
antivir
spectrum
sdz
vivo
studi
avail
capsid
function
inhibitor
synthet
deriv
analogu
base
core
structur
natur
occur
product
rhodanin
fig
synthes
evalu
variou
biolog
system
result
reveal
spectrum
viru
inhibitori
activ
rhodanin
extrem
narrow
concentr
mgml
select
inhibit
echoviru
observ
howev
nontox
uninfect
host
cell
monkey
kidney
cell
concentr
mgml
sever
deriv
analogu
rhodanin
prepar
test
fig
consider
less
potent
rhodanin
bw
illustr
figur
flavanoidlik
skeleton
highli
effect
preval
rhinovir
serotyp
vitro
ic
valu
mmml
mechanist
studi
indic
block
viral
replic
inhibit
stage
immedi
entranc
viral
rna
host
cell
order
improv
potenc
well
broaden
antivir
spectrum
synthet
flavanoid
substitut
halo
cyano
amidino
group
prepar
test
vitro
activ
hrv
polio
cox
echo
among
synthet
flavanoid
test
eg
compound
shown
fig
found
activ
hrv
infect
parent
bw
also
show
good
antienterovir
activ
within
micro
submicromolar
rang
ic
mm
contrast
bw
inact
enterovirus
test
except
cox
moder
activ
observ
mm
among
compound
list
figur
compound
exhibit
potent
activ
ic
mm
howev
rel
imidazolidinon
fig
discov
nhri
taiwan
compound
much
shorter
length
decreas
activ
tenfold
higher
potenc
observ
imidazolidinon
could
attribut
effici
occup
pocket
produc
structur
stabl
virion
dimethoxychalcon
ro
figur
chalconelik
synthet
compound
possess
signific
activ
rhinovirus
show
activ
picornavirus
among
rhinoviru
serotyp
test
sensit
ro
hela
cell
cultur
ic
valu
antivir
activ
around
mgml
cc
cytotox
concentr
mgml
ro
found
ineffect
rhinoviru
infect
human
volunt
probabl
poor
water
solubl
oral
bioavail
studi
variou
analogu
relat
antirhinoviru
agent
led
identif
novel
class
chalcon
amid
analogu
eg
fig
compar
ro
activ
select
hrv
serotyp
concentr
low
ngml
show
low
cytotox
mgml
label
studi
indic
amid
compound
competit
inhibit
bind
ro
h
viral
capsid
site
manner
similar
bw
vp
win
clinic
inform
avail
seri
compound
mode
action
abovement
capsidbind
molecul
experiment
verifi
evid
indic
inhibit
viral
replic
occur
earli
stage
viral
attach
andor
uncoat
compound
mechan
studi
report
also
like
function
capsidbind
molecul
light
linear
structur
profil
well
lipophil
properti
exampl
novel
class
azolyalkyloxi
compound
synthes
synphar
laboratori
inc
edmonton
alberta
canada
believ
mimic
win
disoxaril
activ
compound
seri
typifi
deriv
figur
show
vitro
activ
panel
rhinoviru
serotyp
ic
valu
rang
mgml
also
show
moder
activ
ic
mgml
serotyp
enterovirus
test
moreov
structureact
relationship
studi
reveal
like
win
compound
optim
length
alkyl
chain
two
termin
heterocycl
moieti
seri
either
methylen
unit
sharp
contrast
antipicornavir
agent
diaryl
methan
arakylaminopyridin
shown
figur
benzimidazol
deriv
shown
figur
possess
much
shorter
chain
length
linker
contain
one
two
atom
observ
first
two
class
diaryl
methan
arakylaminopyridin
develop
kenni
et
al
among
compound
evalu
rhinovirus
well
coxsackievir
sever
found
exhibit
moder
activ
ic
rang
mg
ml
base
observ
diaryl
methan
arakylaminopyridin
fig
select
test
larger
panel
picornavirus
vivo
antivir
efficaci
compound
exhibit
similar
vitro
activ
inhibit
picornavirus
test
concentr
less
mgml
addit
arakylaminopyridin
found
activ
vivo
protect
cox
mice
singl
oral
dose
mgkg
continu
oral
dose
mgml
per
day
observ
vitro
potenc
vivo
efficaci
potenti
clinic
applic
treatment
picornaviru
infect
diseas
appear
limit
benzimidazol
analogu
vitro
activ
polio
cox
hrv
enteroviru
test
show
analogu
particularli
effect
enteroviru
ic
valu
low
mgml
cytotox
evalu
use
llcmk
hala
cell
indic
seri
compound
toxic
concentr
mgml
cc
repres
compound
fig
prevent
develop
cox
hypoglycermia
mice
day
infect
given
intraperiton
ip
initi
dose
mgkgday
follow
mgkgday
day
result
clinic
applic
avail
present
time
nand
osubstitut
amino
acid
analogu
synthes
develop
antivir
agent
sever
substitut
glycin
analogu
exemplifi
figur
show
moder
activ
cox
echo
ic
valu
around
mgml
vivo
studi
report
summari
activ
capsidbind
compound
gener
character
long
linear
methylen
spacer
either
aromat
heterocycl
ring
attach
end
make
molecul
consider
hydrophob
genet
point
view
common
structur
featur
impli
structur
socklik
coat
protein
highli
conserv
evolut
piconarvirus
intrins
hydrophob
properti
pocket
well
caviti
shape
well
preserv
therapeut
use
antivir
drug
broad
antivir
spectrum
high
potenc
low
cytotox
therefor
molecul
act
viral
pocket
subtl
differ
size
observ
variou
serotyp
genu
even
differ
genera
could
promis
therapeut
agent
treat
picornavir
infect
date
numer
compound
signific
vitro
activ
hrvand
ev
found
howev
major
compound
shown
previou
section
bind
viral
capsid
inhibit
either
viral
attachmentadsorpt
subsequ
uncoat
addit
agent
interfer
earli
stage
picornavir
life
cycl
attempt
made
recent
develop
inhibitor
block
viruscod
proteas
synthet
stage
viru
replic
antipicornavir
agent
design
target
proteas
highli
conserv
among
differ
viral
serotyp
exhibit
great
potenti
therapeut
util
sinc
peptid
aldehyd
success
use
inhibitor
cystein
serin
proteas
shown
form
revers
coval
adduct
modifi
tripeptid
aldehyd
design
synthes
inhibitor
hrv
molecular
model
base
apo
crystal
structur
trypsinlik
serin
proteas
construct
approxim
bind
peptid
substrat
gener
transit
state
model
p
p
amid
cleavag
sinc
glutamin
deriv
exist
predominantli
cyclic
hemiamin
form
sever
isoster
replac
p
carboxamid
side
chain
design
incorpor
tripeptid
aldehyd
synthes
compound
found
potent
inhibitor
purifi
k
rang
mm
shown
tabl
iii
compound
low
tabl
v
inhibitori
antihrv
activ
cytotox
compound
materi
inthist
istaken
part
ref
micromolar
antivir
activ
low
toxic
reason
therapeut
index
along
line
structurebas
design
ketonecontain
tripeptidyl
hrv
revers
inhibitor
also
report
excel
exampl
compound
eg
display
potent
inhibit
activ
vitro
antivir
properti
test
hrv
see
tabl
iv
tabl
v
also
synthes
inhibit
picornavir
proteas
k
synthes
molecul
found
rang
mm
detail
biolog
screen
result
summar
tabl
v
hrv
proteas
also
inactiv
seri
snitrothiol
includ
snap
gsno
snitrosocaptopril
elafqcgsno
exhibit
inhibitori
activ
timeand
concentrationdepend
manner
secondord
rate
constant
k
inact
k
rang
tabl
vi
inactiv
enzym
shown
reactiv
ddt
gsh
ascorb
indic
inactiv
process
stransnitrosyl
process
new
class
inhibitor
contain
tripeptid
bind
determin
well
micheal
acceptor
moieti
capabl
bind
irrevers
activ
site
cystein
enzym
describ
agent
rhinoviru
tabl
vii
inde
analysi
xray
crystal
structur
reveal
tran
p
gln
amid
hydrogen
atom
interact
proteas
ci
nh
found
expos
solvent
p
lactamcontain
inhibitor
eg
display
enhanc
inhibit
activ
along
improv
antirhinovir
properti
rel
correspond
glutaminederiv
molecul
eg
tabl
viii
one
potent
inhibitor
class
compound
formul
intranas
deliveri
phase
ii
trial
exhibit
better
potenc
broader
spectrum
antirhinovir
activ
pleconaril
toward
clinic
hrv
isol
median
ec
valu
determin
microscop
cpe
inhibit
slightli
better
compar
tabl
x
materi
inthist
istaken
part
ref
pleconaril
p
indistinguish
spectrophotometr
assay
p
case
clinic
hrv
isol
howev
median
ec
valu
determin
either
microscop
spectrophotometr
mgml
found
mgml
pleconaril
symptom
sever
patient
hrvinduc
respiratori
ill
correl
elev
level
inflammatori
cytokin
test
antivir
activ
abil
inhibit
product
human
bronchial
epitheli
cell
line
infect
cell
result
product
infecti
viru
cytokin
treatment
infect
cell
result
dosedepend
reduct
level
infecti
viru
well
reduc
level
cell
supernat
abl
inhibit
replic
viru
cell
order
favor
pharmacokinet
properti
develop
oral
avail
inhibitor
certain
substitut
benzamid
nonpeptid
inhibitor
hrv
invent
bunsatur
keto
benzamid
tabl
ix
show
good
inhibitori
properti
moder
activ
yet
benzamid
tabl
x
found
activ
evalu
revers
nonspecif
inhibitor
hrv
proteas
led
novel
seri
isatin
use
combin
protein
structurebas
drug
design
molecular
model
structureact
relationship
analysi
carbonyl
isatin
envis
react
activ
site
hrv
cystein
respons
catalyt
proteolysi
molecular
model
use
apo
crystal
structur
peptid
substrat
model
provid
design
templat
build
recognit
featur
p
p
subsit
respect
isatin
synthes
compound
see
tabl
xi
found
possess
excel
inhibitori
properti
toward
compar
proteolyt
enzym
includ
chymotrypsin
cathepsin
b
recent
claim
compound
quinon
moieti
well
quinon
analogu
use
inhibitor
cystein
proteas
particular
caspas
cystein
proteas
compound
exemplifi
figur
test
hrv
show
moder
vitro
activ
ic
valu
around
submicro
micromolar
rang
mechanist
assum
act
activ
michael
acceptor
prone
attack
cystein
residu
thu
disrupt
abil
cystein
proteas
cleav
peptid
chain
summari
viral
proteas
play
essenti
role
life
cycl
mani
virus
picornavirus
herpesvirus
retrovirus
coronavirus
therefor
select
target
develop
antivir
drug
proteas
inhibitor
includ
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
avail
treat
diseas
caus
hiv
speci
retrovirus
antipicornaviru
compound
target
proteas
current
activ
investig
among
potenti
treatment
rhinoviru
caus
common
cold
phase
ii
clinic
trial
recent
shown
exhibit
moder
vitro
activ
coronaviru
respons
sever
acut
respiratori
syndrom
sar
model
studi
also
indic
promis
start
point
search
treatment
sar
via
target
proteas
main
proteas
control
coronaviru
replic
